Fig. 4

Silencing miR-455-3p chemosensitizes and reduces the tumorigenesis of PDEC cells. a Analysis of miR-455-3p expression in TCGA (n = 199; P = 0.008; left) and in collected clinical samples (n = 222; P < 0.001; right) indicating that miR-455-3p was significantly upregulated in primary ESCC. b Kaplan–Meier analysis of overall and disease-free survival curves for patients with ESCC exhibiting low or high miR-455-3p expression. c Annexin V-FITC/PI staining of the indicated cells treated with cisplatin (20 μM) or DOC (1.5 nM) for 24 h. d Representative images of tumor-bearing mice (left) and weight of xenografts (right) derived from the indicated CDDP-treated cells. e Flow cytometry analysis of the percentages of CD90⁺/CD271⁺ subpopulations in the indicated cells. f Representative images (left) and quantification (right) of tumorspheres formed by the indicated cells. Each bar represents the mean ± SD of three independent experiments. * P < 0.05